Guardant Health, Inc. develops precision oncology diagnostics and data products centered on blood and tissue testing for cancer care. Company news commonly covers the Guardant360 liquid biopsy and Guardant360 Tissue franchises, Guardant Reveal for molecular residual disease monitoring, Shield colorectal cancer screening, and InfinityAI real-world data and analytics.
Recurring updates include financial results across Oncology, Screening, and Biopharma & Data revenue categories; FDA companion diagnostic approvals for Guardant360 CDx; research presentations in tumor typing, therapy selection, methylation and multiomic testing; and biopharma collaborations that use Guardant tissue and liquid biopsy assays to support targeted therapy development.
Guardant Health (Nasdaq: GH) will present over 25 abstracts at the ASCO Annual Meeting and AACR Virtual Meeting, showcasing their blood tests for precision oncology. Key findings include Guardant360 and GuardantOMNI tests demonstrating high concordance with tissue biopsies. The LUNAR-2 liquid biopsy showed 90.3% sensitivity in detecting early-stage colorectal cancer, while data supports the use of ctDNA for drug development and monitoring. Ongoing trials include LUNAR-1, validating the clinical utility of liquid biopsy in adjuvant treatment for colon cancer.
Guardant Health, Inc. (Nasdaq: GH) reported first-quarter 2020 revenue of $67.5 million, an 84% increase year-over-year. The company performed 15,257 clinical tests, a 60% increase, and 5,266 biopharmaceutical tests, a 40% increase. Precision oncology revenue soared 109% due to rising testing volume and average price. However, operating expenses rose 75.1% to $81.9 million, leading to a net loss of $27.7 million. Guardant Health withdrew its 2020 financial guidance due to COVID-19 uncertainties. Cash reserves stood at $758.3 million.
Guardant Health, a leader in precision oncology, will participate in the BofA Securities Virtual Healthcare Conference on May 13, 2020, at 1:20 p.m. PT. The event can be accessed via a live webcast on their website.
The company focuses on enhancing cancer care through proprietary blood tests and analytics, including Guardant360 and GuardantOMNI for advanced cancer patients. Additionally, Guardant Health's LUNAR program targets early-stage cancer detection and treatment options.
Guardant Health has launched the Clear Your View campaign to promote complete biomarker testing for advanced non-small cell lung cancer (NSCLC) patients. Current guidelines recommend testing for 10 tumor biomarkers, yet less than 20% of patients receive comprehensive testing. The campaign, supported by major patient advocacy groups, aims to raise awareness among oncologists about the importance of thorough testing before starting treatment. This is particularly crucial during the COVID-19 pandemic as targeted therapies can provide more effective treatment options. Over 10,000 oncologists will receive information on the campaign.
Summary not available.
Summary not available.